Company
ADmit THERAPEUTICS
- Biotech
- Location:
- Barcelona, Spain
Description
ADmit THERAPEUTICS develops and commercializes MAP-AD®, an in vitro diagnostic test using mitochondrial DNA epigenetic biomarkers, NGS and machine learning for early detection and prognosis of Alzheimer’s dementia.
ADmit THERAPEUTICS is located in the Barcelona ecosystem.
Related
Age LabsAge Labs develops biomarkers and predictive algorithms for early detection of age-related diseases, offering diagnostic tests, biological…
Sequentia BiotechSequentia Biotech provides bioinformatics solutions, custom software, and expert consulting that analyze multiomics and NGS data for…
AidianAidian develops, manufactures, and distributes CE‑marked in vitro diagnostic tests and point‑of‑care products for clinical diagnostics and…
Pharmasum TherapeuticsPharmasum Therapeutics discovers and develops neurological-disease drugs, including PST-674, a proprietary DYRK1A inhibitor intended to…
SulfateqSulfateq develops SUL compounds from research into natural mitochondrial stress responses, using a distinct mechanism of action to address…
- DeepullDeepull develops the UllCORE BSI test and supporting instrument that perform direct-from-blood multiplex molecular detection of pathogens…
BiohitBiohit develops diagnostic products and services for medical research and early detection, producing assays, clinical study protocols and…
Devyser DiagnosticsDevyser Diagnostics develops DNA test kits and integrated software for laboratory DNA diagnostics, helping labs run genetic testing…
Nimble DiagnosticsNimble Diagnostics develops a non-invasive, portable monitoring device that detects stent complications, measuring stent malfunction with…